Chofit Chai1, Bryan Cox2, Dayana Yaish1, Devora Gross1, Nofar Rosenberg1, Franck Amblard2, Zohar Shemuelian1, Maytal Gefen1, Amit Korach3, Oren Tirosh4, Tali Lanton1, Henrike Link1, Joseph Tam5, Anna Permyakova5, Gunes Ozhan6, Jonathan Citrin1, Haixing Liao7, Mirna Tannous1, Michal Hahn4, Jonathan Axelrod1, Enara Arretxe8, Cristina Alonso8, Ibon Martinez-Arranz8, Pablo Ortiz Betés8, Rifaat Safadi9, Ahmad Salhab9, Johnny Amer9, Zahira Tber2, Seema Mengshetti2, Hilla Giladi1, Raymond F Schinazi10, Eithan Galun11. 1. Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel. 2. Laboratory of Biochemical Pharmacology Emory University, Department of Pediatrics, Atlanta, Georgia. 3. Cardiothoracic Surgery, Hadassah Hebrew University Hospital, Jerusalem, Israel. 4. Institute of Biochemistry, Food Science and Nutrition, The Robert H. Smith Faculty of Agriculture, Food, and Environment, The Hebrew University of Jerusalem, Rehovot, Israel. 5. Obesity and Metabolism Laboratory, Multidisciplinary Center for Cannabinoid Research, Faculty of Medicine, The Institute for Drug Research, The Hebrew University of Jerusalem, Israel. 6. Izmir Biomedicine and Genome Center, Dokuz Eylul University Health Campus, Izmir, Turkey. 7. The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 8. OWL Metabolomics, Bizkaia Technology Park, Derio, Spain. 9. Liver Unit, Gastroenterology Institute, Department of Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel. 10. Laboratory of Biochemical Pharmacology Emory University, Department of Pediatrics, Atlanta, Georgia. Electronic address: raymond.schinazi@emory.edu. 11. Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel. Electronic address: eithang@hadassah.org.il.
Abstract
BACKGROUND & AIMS: Development of nonalcoholic steatohepatitis (NASH) is associated with reductions in hepatic microRNA122 (MIR122); the RAR related orphan receptor A (RORA) promotes expression of MIR122. Increasing expression of RORA in livers of mice increases expression of MIR122 and reduces lipotoxicity. We investigated the effects of a RORA agonist in mouse models of NASH. METHODS: We screened a chemical library to identify agonists of RORA and tested their effects on a human hepatocellular carcinoma cell line (Huh7). C57BL/6 mice were fed a chow or high-fat diet (HFD) for 4 weeks to induce fatty liver. Mice were given hydrodynamic tail vein injections of a MIR122 antagonist (antagomiR-122) or a control antagomiR once each week for 3 weeks while still on the HFD or chow diet, or intraperitoneal injections of the RORA agonist RS-2982 or vehicle, twice each week for 3 weeks. Livers, gonad white adipose, and skeletal muscle were collected and analyzed by reverse-transcription polymerase chain reaction, histology, and immunohistochemistry. A separate group of mice were fed an atherogenic diet, with or without injections of RS-2982 for 3 weeks; livers were analyzed by immunohistochemistry, and plasma was analyzed for levels of aminotransferases. We analyzed data from liver tissues from patients with NASH included in the RNA-sequencing databases GSE33814 and GSE89632. RESULTS: Injection of mice with antagomiR-122 significantly reduced levels of MIR122 in plasma, liver, and white adipose tissue; in mice on an HFD, antagomiR-122 injections increased fat droplets and total triglyceride content in liver and reduced β-oxidation and energy expenditure, resulting in significantly more weight gain than in mice given the control microRNA. We identified RS-2982 as an agonist of RORA and found it to increase expression of MIR122 promoter activity in Huh7 cells. In mice fed an HFD or atherogenic diet, injections of RS-2982 increased hepatic levels of MIR122 precursors and reduced hepatic synthesis of triglycerides by reducing expression of biosynthesis enzymes. In these mice, RS-2982 significantly reduced hepatic lipotoxicity, reduced liver fibrosis, increased insulin resistance, and reduced body weight compared with mice injected with vehicle. Patients who underwent cardiovascular surgery had increased levels of plasma MIR122 compared to its levels before surgery; increased expression of plasma MIR122 was associated with increased levels of plasma free fatty acids and levels of RORA. CONCLUSIONS: We identified the compound RS-2982 as an agonist of RORA that increases expression of MIR122 in cell lines and livers of mice. Mice fed an HFD or atherogenic diet given injections of RS-2982 had reduced hepatic lipotoxicity, liver fibrosis, and body weight compared with mice given the vehicle. Agonists of RORA might be developed for treatment of NASH.
BACKGROUND & AIMS: Development of nonalcoholic steatohepatitis (NASH) is associated with reductions in hepatic microRNA122 (MIR122); the RAR related orphan receptor A (RORA) promotes expression of MIR122. Increasing expression of RORA in livers of mice increases expression of MIR122 and reduces lipotoxicity. We investigated the effects of a RORA agonist in mouse models of NASH. METHODS: We screened a chemical library to identify agonists of RORA and tested their effects on a humanhepatocellular carcinoma cell line (Huh7). C57BL/6 mice were fed a chow or high-fat diet (HFD) for 4 weeks to induce fatty liver. Mice were given hydrodynamic tail vein injections of a MIR122 antagonist (antagomiR-122) or a control antagomiR once each week for 3 weeks while still on the HFD or chow diet, or intraperitoneal injections of the RORA agonist RS-2982 or vehicle, twice each week for 3 weeks. Livers, gonad white adipose, and skeletal muscle were collected and analyzed by reverse-transcription polymerase chain reaction, histology, and immunohistochemistry. A separate group of mice were fed an atherogenic diet, with or without injections of RS-2982 for 3 weeks; livers were analyzed by immunohistochemistry, and plasma was analyzed for levels of aminotransferases. We analyzed data from liver tissues from patients with NASH included in the RNA-sequencing databases GSE33814 and GSE89632. RESULTS: Injection of mice with antagomiR-122 significantly reduced levels of MIR122 in plasma, liver, and white adipose tissue; in mice on an HFD, antagomiR-122 injections increased fat droplets and total triglyceride content in liver and reduced β-oxidation and energy expenditure, resulting in significantly more weight gain than in mice given the control microRNA. We identified RS-2982 as an agonist of RORA and found it to increase expression of MIR122 promoter activity in Huh7 cells. In mice fed an HFD or atherogenic diet, injections of RS-2982 increased hepatic levels of MIR122 precursors and reduced hepatic synthesis of triglycerides by reducing expression of biosynthesis enzymes. In these mice, RS-2982 significantly reduced hepatic lipotoxicity, reduced liver fibrosis, increased insulin resistance, and reduced body weight compared with mice injected with vehicle. Patients who underwent cardiovascular surgery had increased levels of plasmaMIR122 compared to its levels before surgery; increased expression of plasmaMIR122 was associated with increased levels of plasmafree fatty acids and levels of RORA. CONCLUSIONS: We identified the compound RS-2982 as an agonist of RORA that increases expression of MIR122 in cell lines and livers of mice. Mice fed an HFD or atherogenic diet given injections of RS-2982 had reduced hepatic lipotoxicity, liver fibrosis, and body weight compared with mice given the vehicle. Agonists of RORA might be developed for treatment of NASH.
Authors: Bianca M Arendt; Elena M Comelli; David W L Ma; Wendy Lou; Anastasia Teterina; TaeHyung Kim; Scott K Fung; David K H Wong; Ian McGilvray; Sandra E Fischer; Johane P Allard Journal: Hepatology Date: 2015-02-27 Impact factor: 17.425
Authors: Rohit Loomba; Zeid Kayali; Mazen Noureddin; Peter Ruane; Eric J Lawitz; Michael Bennett; Lulu Wang; Eliza Harting; Jacqueline M Tarrant; Bryan J McColgan; Chuhan Chung; Adrian S Ray; G Mani Subramanian; Robert P Myers; Michael S Middleton; Michelle Lai; Michael Charlton; Stephen A Harrison Journal: Gastroenterology Date: 2018-07-27 Impact factor: 22.682
Authors: Christine Esau; Scott Davis; Susan F Murray; Xing Xian Yu; Sanjay K Pandey; Michael Pear; Lynnetta Watts; Sheri L Booten; Mark Graham; Robert McKay; Amuthakannan Subramaniam; Stephanie Propp; Bridget A Lollo; Susan Freier; C Frank Bennett; Sanjay Bhanot; Brett P Monia Journal: Cell Metab Date: 2006-02 Impact factor: 27.287
Authors: Scott L Friedman; Vlad Ratziu; Stephen A Harrison; Manal F Abdelmalek; Guruprasad P Aithal; Juan Caballeria; Sven Francque; Geoffrey Farrell; Kris V Kowdley; Antonio Craxi; Krzysztof Simon; Laurent Fischer; Liza Melchor-Khan; Jeffrey Vest; Brian L Wiens; Pamela Vig; Star Seyedkazemi; Zachary Goodman; Vincent Wai-Sun Wong; Rohit Loomba; Frank Tacke; Arun Sanyal; Eric Lefebvre Journal: Hepatology Date: 2018-01-29 Impact factor: 17.425
Authors: Tung T Nguyen; John S A Mattick; Qian Yang; Mehmet A Orman; Marianthi G Ierapetritou; Francois Berthiaume; Ioannis P Androulakis Journal: BMC Bioinformatics Date: 2014-03-25 Impact factor: 3.169